Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
Paul Nathan*, Paolo A. Ascierto, John Haanen, Enrique Espinosa, Lev Demidov, Claus Garbe, Michele Guida, Paul Lorigan, Vanna Chiarion-Sileni, Helen Gogas, Michele Maio, Maria Teresa Fierro, Christoph Hoeller, Patrick Terheyden, Ralf Gutzmer, Tormod K. Guren, Dimitrios Bafaloukos, Piotr Rutkowski, Ruth Plummer, Ashita Waterston
*Korrespondierende/r Autor/-in für diese Arbeit
- Mount Vernon Hospital
- Istituto Nazionale Dei Tumori Napoli
- Antoni Van Leeuwenhoek Ziekenhuis
- Instituto de Investigacion Sanitaria del Hospital Universitario La Paz (IdiPAZ)
- Ministry of Health of Russian Federation
- Eberhard Karls Universität Tübingen
- IRCCS Istituto Tumori “Giovanni Paolo II”
- University of Manchester
- University of Padova
- University of Athens Medical School
- University of Siena
- University of Torino
- University of Vienna
- Medizinische Hochschule Hannover
- University of Oslo
- Metropolitan Hospital, Athens
- Center of Oncology
- Newcastle University
- Beatson Oncology Centre
- ASST Papa Giovanni XXIII
- General University Hospital
- Vall D′Hebron University
- Universität Zürich
- Bristol-Myers Squibb
- Universität Duisburg-Essen
85
Link öffnet neuen Tab
Zitate (Scopus)